Cargando…
A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite
BACKGROUND: Reduced appetite is a common clinical sign in dogs. This study evaluated the effectiveness and safety of capromorelin oral solution, (ENTYCE(®), Aratana Therapeutics, Leawood, KS) a new drug that is a ghrelin receptor agonist, for stimulation of appetite in dogs with reduced appetite. HY...
Autores principales: | Zollers, B., Wofford, J.A., Heinen, E., Huebner, M., Rhodes, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115193/ https://www.ncbi.nlm.nih.gov/pubmed/27859746 http://dx.doi.org/10.1111/jvim.14607 |
Ejemplares similares
-
Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs
por: Rhodes, Linda, et al.
Publicado: (2017) -
A Prospective, Randomized, Masked, Placebo‐Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis
por: Rausch‐Derra, L., et al.
Publicado: (2016) -
Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study
por: Zollers, Bill, et al.
Publicado: (2017) -
A prospective, randomized, masked, placebo‐controlled crossover study for the effect of 10 mg omeprazole capsules on gastric pH in healthy dogs
por: Gaier, Ann, et al.
Publicado: (2021) -
Evaluation of Weight Loss Over Time in Cats with Chronic Kidney Disease
por: Freeman, L.M., et al.
Publicado: (2016)